Fig. 2
The cost-effectiveness acceptability curve (CEAC) of the early economic evaluation of the new prognostic tool, Straticyte™. Net monetary benefit is used to determine which treatment was cost-effective for each simulation at different willingness to pay thresholds (WTPs) for cancer cases avoided given the use of Staricyte™ (i.e. biomarker) in combination with the standard of care (i.e. Histopathology)